• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用30微克药敏纸片对FK-037进行初步解释性药敏试验标准。

Preliminary interpretive susceptibility testing criteria for FK-037 with 30-microgram disks.

作者信息

Jones R N

机构信息

Department of Pathology, University of Iowa College of Medicine, Iowa City 52242.

出版信息

J Clin Microbiol. 1994 Apr;32(4):1104-6. doi: 10.1128/jcm.32.4.1104-1106.1994.

DOI:10.1128/jcm.32.4.1104-1106.1994
PMID:8027323
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC267197/
Abstract

FK-037, a new parenteral cephalosporin, was tested against 483 organisms from clinical infections to establish preliminary susceptibility testing criteria with 30-micrograms disks. The proposed breakpoint zone diameters were > or = 17 mm (MIC correlate, < or = 8 micrograms/ml) for the susceptible category and < or = 13 mm (MIC correlate, > or = 32 micrograms/ml) for the resistant category. These interpretive guidelines produced no very major (false-susceptible) errors, 2.9% major (false-resistant) errors, and 6.2% minor errors for a total absolute agreement between methods of 90.9%.

摘要

新型肠胃外头孢菌素FK-037针对483株临床感染分离菌进行了测试,以确立30微克纸片法的初步药敏试验标准。对于敏感类别,建议的折点抑菌圈直径为≥17毫米(对应的最低抑菌浓度,≤8微克/毫升);对于耐药类别,为≤13毫米(对应的最低抑菌浓度,≥32微克/毫升)。这些解释性指南产生的极重大(假敏感)错误为零,重大(假耐药)错误为2.9%,次要错误为6.2%,两种方法之间的总绝对符合率为90.9%。

相似文献

1
Preliminary interpretive susceptibility testing criteria for FK-037 with 30-microgram disks.使用30微克药敏纸片对FK-037进行初步解释性药敏试验标准。
J Clin Microbiol. 1994 Apr;32(4):1104-6. doi: 10.1128/jcm.32.4.1104-1106.1994.
2
In vitro activity and beta-lactamase stability of FK-037, a parenteral cephalosporin.注射用头孢菌素FK-037的体外活性及β-内酰胺酶稳定性
Antimicrob Agents Chemother. 1993 Mar;37(3):566-73. doi: 10.1128/AAC.37.3.566.
3
Interpretive criteria of antimicrobial disk susceptibility tests with cefpodoxime.头孢泊肟抗菌药敏试验的解释标准
Infection. 1991 Sep-Oct;19(5):380-2. doi: 10.1007/BF01645373.
4
Haemophilus test medium interpretive criteria for disk diffusion susceptibility tests with cefdinir, cefetamet, cefmetazole, cefpodoxime, cefdaloxime (RU29246, HR-916 metabolite), and trospectomycin.用于头孢地尼、头孢他美、头孢美唑、头孢泊肟、头孢达肟(RU29246,HR - 916代谢物)和曲氟沙星纸片扩散药敏试验的嗜血杆菌检测培养基解释标准。
Diagn Microbiol Infect Dis. 1992 Nov-Dec;15(8):693-701. doi: 10.1016/0732-8893(92)90073-3.
5
Interpretive criteria for susceptibility tests with DU-6859a and FK-037 tested against Haemophilus influenzae and Neisseria gonorrhoeae.针对流感嗜血杆菌和淋病奈瑟菌对DU-6859a和FK-037进行药敏试验的解释标准。
Diagn Microbiol Infect Dis. 1994 Jun;19(2):93-9. doi: 10.1016/0732-8893(94)90119-8.
6
Interpretive criteria for CI-960 (AM-1091, PD127391) disk diffusion tests using 5-microgram disks.使用5微克纸片进行CI-960(AM-1091,PD127391)纸片扩散试验的解释标准。
Diagn Microbiol Infect Dis. 1992 May-Jun;15(4):379-81. doi: 10.1016/0732-8893(92)90029-s.
7
In vitro activity of Ro 19-5247 (T-2525) and interpretive criteria for disk diffusion susceptibility testing.Ro 19-5247(T-2525)的体外活性及纸片扩散法药敏试验的解释标准
J Clin Microbiol. 1987 Jul;25(7):1186-90. doi: 10.1128/jcm.25.7.1186-1190.1987.
8
Preliminary antimicrobial susceptibility interpretive criteria for cefetamet (Ro 15-8074) and cefteram (Ro 19-5247) disk tests.头孢他美酯(Ro 15-8074)和头孢特仑(Ro 19-5247)纸片试验的初步抗菌药物敏感性解释标准。
J Clin Microbiol. 1987 Sep;25(9):1796-9. doi: 10.1128/jcm.25.9.1796-1799.1987.
9
Comparative in vitro activity of FK-037, a new cephalosporin antibiotic.新型头孢菌素抗生素FK-037的体外活性比较
Diagn Microbiol Infect Dis. 1994 Sep;20(1):27-32. doi: 10.1016/0732-8893(94)90015-9.
10
Prediction of bacterial susceptibility to cefpodoxime by using the ceftriaxone minimum inhibitory concentration result.利用头孢曲松最低抑菌浓度结果预测细菌对头孢泊肟的敏感性
Diagn Microbiol Infect Dis. 1993 Nov-Dec;17(4):313-6. doi: 10.1016/0732-8893(93)90041-5.

本文引用的文献

1
In vitro activity and beta-lactamase stability of FK-037, a parenteral cephalosporin.注射用头孢菌素FK-037的体外活性及β-内酰胺酶稳定性
Antimicrob Agents Chemother. 1993 Mar;37(3):566-73. doi: 10.1128/AAC.37.3.566.
2
In vitro and in vivo antibacterial activities of FK037, a novel parenteral broad-spectrum cephalosporin.新型注射用广谱头孢菌素FK037的体外和体内抗菌活性
Antimicrob Agents Chemother. 1993 Feb;37(2):301-7. doi: 10.1128/AAC.37.2.301.
3
Antimicrobial activity of FK-037 against class I beta-lactamase producing species resistant to ceftazidime: a multi-laboratory clinical isolate sample.FK-037对产I类β-内酰胺酶且对头孢他啶耐药的菌株的抗菌活性:多实验室临床分离株样本
J Antimicrob Chemother. 1993 Oct;32(4):654-6. doi: 10.1093/jac/32.4.654.
4
In vitro evaluation of HR810, a new wide-spectrum aminothiazolyl alpha-methoxyimino cephalosporin.新型广谱氨噻唑基α-甲氧基氨基头孢菌素HR810的体外评价
Antimicrob Agents Chemother. 1984 Jun;25(6):710-8. doi: 10.1128/AAC.25.6.710.
5
Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin.新型广谱头孢菌素BMY-28142的体外活性评估
Antimicrob Agents Chemother. 1985 May;27(5):679-82. doi: 10.1128/AAC.27.5.679.
6
In vitro antibacterial spectrum of E1040 compared with those of cefpirome and ceftazidime and disk diffusion interpretive criteria for E1040.E1040的体外抗菌谱与头孢匹罗和头孢他啶的抗菌谱比较以及E1040的纸片扩散法解释标准。
Antimicrob Agents Chemother. 1990 May;34(5):914-7. doi: 10.1128/AAC.34.5.914.